Efficacy and Safety of Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor Therapy for Anemia in Renal Transplantation Patients by Prior Erythropoiesis Stimulating Agent Use.

[1]  T. Yokoyama,et al.  Therapeutic Effect of Roxadustat on Patients With Posttransplant Anemia. , 2022, Transplantation proceedings.

[2]  J. Uchida,et al.  Experience With the Use of a Novel Agent, Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor, for Posttransplant Anemia in Renal Transplant Recipients: A Case Report. , 2022, Transplantation proceedings.

[3]  Y. Ubara,et al.  Correcting anemia and native vitamin D supplementation in kidney transplant recipients: a multicenter, 2 × 2 factorial, open‐label, randomized clinical trial , 2021, Transplant international : official journal of the European Society for Organ Transplantation.

[4]  M. Nangaku,et al.  Phase 3 Randomized Study Comparing Vadadustat with Darbepoetin Alfa for Anemia in Japanese Patients with Nondialysis-Dependent CKD , 2021, Journal of the American Society of Nephrology : JASN.

[5]  M. Iwasaki,et al.  Phase 3 Study of Roxadustat to Treat Anemia in Non–Dialysis-Dependant CKD , 2021, Kidney international reports.

[6]  T. Akizawa,et al.  A Phase 3, Multicenter, Randomized, Two-Arm, Open-Label Study of Intermittent Oral Dosing of Roxadustat for the Treatment of Anemia in Japanese Erythropoiesis-Stimulating Agent-Naïve Chronic Kidney Disease Patients Not on Dialysis , 2020, Nephron.

[7]  L. Szczech,et al.  Roxadustat for Anemia in Patients with Kidney Disease Not Receiving Dialysis. , 2019, The New England journal of medicine.

[8]  L. Szczech,et al.  Roxadustat Treatment for Anemia in Patients Undergoing Long-Term Dialysis. , 2019, The New England journal of medicine.

[9]  N. Goto,et al.  The effect of maintaining high hemoglobin levels on long-term kidney function in kidney transplant recipients: a randomized controlled trial , 2018, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[10]  L. Rostaing,et al.  Correction of postkidney transplant anemia reduces progression of allograft nephropathy. , 2012, Journal of the American Society of Nephrology : JASN.